JP2007527904A - グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物 - Google Patents

グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物 Download PDF

Info

Publication number
JP2007527904A
JP2007527904A JP2007502390A JP2007502390A JP2007527904A JP 2007527904 A JP2007527904 A JP 2007527904A JP 2007502390 A JP2007502390 A JP 2007502390A JP 2007502390 A JP2007502390 A JP 2007502390A JP 2007527904 A JP2007527904 A JP 2007527904A
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
alkoxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007502390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007527904A5 (https=
Inventor
スチュアート・エドワード・ブラッドリー
レバティ・ペルペチュア・ジーヴァラトナム
トーマス・マルティン・クルレ
マーティン・ジェイムズ・プロクター
ロバート・ジョン・ローリー
ジェラード・ヒュー・トーマス
アナ・バルデス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of JP2007527904A publication Critical patent/JP2007527904A/ja
Publication of JP2007527904A5 publication Critical patent/JP2007527904A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007502390A 2004-03-08 2005-03-08 グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物 Withdrawn JP2007527904A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55125404P 2004-03-08 2004-03-08
PCT/GB2005/000885 WO2005085245A1 (en) 2004-03-08 2005-03-08 Pyrrolopyridine-2-carboxylic acid hydrazides

Publications (2)

Publication Number Publication Date
JP2007527904A true JP2007527904A (ja) 2007-10-04
JP2007527904A5 JP2007527904A5 (https=) 2008-02-07

Family

ID=34919586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007502390A Withdrawn JP2007527904A (ja) 2004-03-08 2005-03-08 グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物

Country Status (7)

Country Link
US (1) US7884112B2 (https=)
EP (1) EP1725555B1 (https=)
JP (1) JP2007527904A (https=)
AT (1) ATE483708T1 (https=)
DE (1) DE602005023965D1 (https=)
ES (1) ES2353309T3 (https=)
WO (1) WO2005085245A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009144056A (ja) * 2007-12-14 2009-07-02 Nagoya City ポリ乳酸用造核剤及びポリ乳酸樹脂組成物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
WO2010089292A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
AU2010262036B2 (en) 2009-05-07 2014-10-30 Cellzome Limited Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
JP2012532912A (ja) 2009-07-15 2012-12-20 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド ガンマセクレターゼモジュレーターとしての置換されたトリアゾールおよびイミダゾール誘導体
BR112012017310A2 (pt) 2010-01-15 2016-04-19 Janssen Pharmaceuticals Inc derivados de triazol substituídos como moduladores de gama secretase
AU2012230348A1 (en) 2011-03-24 2013-08-29 Cellzome Limited Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
KR101913135B1 (ko) 2011-07-15 2018-10-30 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체
US9181245B2 (en) 2012-05-16 2015-11-10 Janssen Pharmaceuticals, Inc. Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
CA2889249C (en) 2012-12-20 2021-02-16 Francois Paul Bischoff Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
CA2891755C (en) 2013-01-17 2021-10-26 Janssen Pharmaceutica Nv Substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618188D0 (en) 1986-07-25 1986-09-03 Ici Plc Diamine compounds
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8813356D0 (en) 1988-06-06 1988-07-13 Ici Plc Polypeptide compounds
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
US5821241A (en) 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists
US5885967A (en) 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
WO1995024186A1 (en) 1994-03-11 1995-09-14 Pharmacopeia, Inc. Sulfonamide derivatives and their use
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
US6001811A (en) 1994-11-21 1999-12-14 Cortech Inc. Serine protease inhibitors--N-substituted derivatives
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
TW394764B (en) 1995-02-14 2000-06-21 Mitsubishi Chemcal Corp Oxygen-containing heterocyclic derivatives
DE19516483A1 (de) 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
WO1996036595A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
FI974437A7 (fi) 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
CA2224062C (en) 1995-06-06 2001-09-04 Pfizer Limited Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
DE69634822T2 (de) 1995-08-22 2006-04-27 Japan Tobacco Inc. Amid-verbindungen und ihre anwendung
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
IL119466A (en) 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
EP0874638A4 (en) 1995-11-13 1999-07-21 Smithkline Beecham Corp HEMATOREGULATORS
US6107309A (en) 1995-11-13 2000-08-22 Smithkline Beecham Corporation Hemoregulatory compounds
FR2744361B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
RU2191193C2 (ru) 1996-02-13 2002-10-20 Акцо Нобель Н.В. Ингибиторы серинпротеазы
WO1997031016A2 (en) 1996-02-23 1997-08-28 Ariad Pharmaceuticals, Inc. New inhibitors of sh2-mediated processes
IL120310A (en) 1996-03-01 2002-02-10 Akzo Nobel Nv Serine protease inhibitors and pharmaceuticals containing them
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO2000006550A1 (en) 1998-07-31 2000-02-10 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
AU4796700A (en) 1999-05-13 2000-12-05 Dupont Pharmaceuticals Research Laboratories, Inc. Ureido-substituted cyclic amine derivatives and their use as drug
DE60023878T2 (de) 1999-05-18 2006-07-20 Teijin Ltd. Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen
EP1192135A2 (en) 1999-06-14 2002-04-03 Eli Lilly And Company Serine protease inhibitors
WO2001002424A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US7576117B1 (en) 1999-08-04 2009-08-18 Teijin Limited Cyclic amine CCR3 antagonist
DE60007592T2 (de) 1999-09-30 2004-09-16 Pfizer Products Inc., Groton Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
JP2003523356A (ja) 2000-01-29 2003-08-05 エルジー シーアイ リミテッド アリール−アミジンを持つＸａ因子阻害剤とその誘導体、及びそれらのプロドラッグ
US6797504B1 (en) 2000-09-08 2004-09-28 Dendreon San Diego Llc Inhibitors of serine protease activity of matriptase or MTSP1
WO2001062775A2 (en) 2000-02-23 2001-08-30 Zealand Pharma A/S Novel antiarrhythmic peptides
AR027656A1 (es) 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
WO2001094310A1 (en) 2000-06-07 2001-12-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for making bis-heterocyclic alkaloids
WO2001096346A1 (en) 2000-06-14 2001-12-20 Eli Lilly And Company Tricyclic compounds as mrp1-inhibitors
IL144507A0 (en) 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
US6277877B1 (en) 2000-08-15 2001-08-21 Pfizer, Inc. Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
AU2001279612A1 (en) 2000-08-18 2002-03-04 H. Lundbeck, A/S Substituted polyamine compounds
CA2321348A1 (en) 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
GB2369117A (en) 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
BR0115938A (pt) 2000-12-06 2003-12-23 Aventis Pharma Deustschland Gm Derivados de guanidina e amidina com inibidores do fator xa
CA2465382A1 (en) * 2001-10-29 2003-05-08 Japan Tobacco Inc. Indole compound and medicinal use thereof
MXPA05012547A (es) * 2003-05-21 2006-05-25 Prosidion Ltd Inhibidores de amida de acido pirrolopiridina-2-carboxilico de fosforilasa de glucogeno.
WO2004113345A1 (ja) 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009144056A (ja) * 2007-12-14 2009-07-02 Nagoya City ポリ乳酸用造核剤及びポリ乳酸樹脂組成物

Also Published As

Publication number Publication date
ES2353309T3 (es) 2011-03-01
ATE483708T1 (de) 2010-10-15
EP1725555B1 (en) 2010-10-06
DE602005023965D1 (de) 2010-11-18
US20080269277A1 (en) 2008-10-30
WO2005085245A8 (en) 2005-11-10
WO2005085245A1 (en) 2005-09-15
EP1725555A1 (en) 2006-11-29
US7884112B2 (en) 2011-02-08

Similar Documents

Publication Publication Date Title
RU2059637C1 (ru) Гетероциклические производные замещенных 2-ациламино-5-тиазолов, способы их получения, производное замещенного 2-аминотиазола, производные 2-амино-4-фенилтиазола
JP5669691B2 (ja) グリコーゲンホスホリラーゼのピロロピリジン−２−カルボン酸アミドインヒビター
JP3035253B2 (ja) 異項環置換アシルアミノチアゾールを含む医薬組成物
JP2001518895A (ja) ソマトスタチン作働薬
JPH08176145A (ja) アロイル−ピペリジン誘導体
JP2001519812A (ja) ソマトスタチン作動薬
JP2001514227A (ja) ピラジノン系トロンビン阻害薬
JP4643989B2 (ja) アンドロゲン受容体関連障害の治療に有用なインドール
JP2007527904A (ja) グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物
US8158622B2 (en) Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2021233427A1 (zh) 并环化合物及其制备方法、药物组合物和应用
JP2016510784A (ja) カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤
WO2005085245A9 (en) Pyrrolopyridine-2-carboxylic acid hydrazides
ES2324173T3 (es) Amidas del acido pirrolopiridin-2-carboxilico.
WO2006071775A2 (en) Novel compounds useful for bradykinin b1 receptor antagonism
JPH07500604A (ja) 高血圧治療用エチルアラニンアミノジオール化合物
JP2007527903A (ja) インドール−２−カルボン酸ヒドラジド化合物
WO2006059163A1 (en) Treatment of diabetes with glycogen phosphorylase inhibitors
SG181594A1 (en) [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
US8664397B2 (en) Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
JP4824092B2 (ja) 新規なビニル様酸誘導体
CA2889538A1 (en) 1h-indole-3-carboxamide derivatives, and use thereof as p2y12 antagonists
JP2008521787A (ja) インドール−２−カルボン酸アミド
JPH05271187A (ja) ピロリジン誘導体又はその薬学的に許容される塩
HK1107984B (en) Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071212

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110126